A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19

A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19

Nelfinavir, an orally administered inhibitor of human immunodeficiency virus protease, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <i>in vitro</i>. We conducted a randomized controlled trial to evaluate the clinical efficacy and safety of nelf...

Full description

Bibliographic Details
Main Authors: Miyazaki, T, Hosogaya, N, Fukushige, Y, Takemori, S, Morimoto, S, Yamamoto, H, Hori, M, Ozawa, Y, Shiko, Y, Inaba, Y, Kurokawa, T, Hanaoka, H, Iwanami, S, Kim, K, Iwami, S, Watashi, K, Miyazawa, K, Umeyama, T, Yamagoe, S, Miyazaki, Y, Wakita, T, Sumiyoshi, M, Hirayama, T, Izumikawa, K, Yanagihara, K, Mukae, H, Kawasuji, H, Yamamoto, Y, Tarumoto, N, Ishii, H, Ohno, H, Yatera, K, Kakeya, H, Kichikawa, Y, Kato, Y, Matsumoto, T, Saito, M, Yotsuyanagi, H, Kohno, S
Format: Journal article
Language:English
Published: American Society for Microbiology 2023

Similar Items